Analytical methods for determination of terbinafine hydrochloride in pharmaceuticals and biological materials  by Kanakapura, Basavaiah & Penmatsa, Vamsi Krishna
Journal of Pharmaceutical Analysis 6 (2016) 137–149H O S T E D  B Y Contents lists available at ScienceDirectjournal homepage: www.elsevier.com/locate/jpa
Journal of Pharmaceutical Analysishttp://d
2095-17
(http://c
$Pee
n Corr
E-mwww.sciencedirect.comReview PaperAnalytical methods for determination of terbinaﬁne hydrochloride
in pharmaceuticals and biological materials$
Basavaiah Kanakapura n, Vamsi Krishna Penmatsa
Department of Chemistry, University of Mysore, Manasagangotri, Mysore 570006, Karnataka, Indiaa r t i c l e i n f o
Article history:
Received 28 February 2015
Received in revised form
17 January 2016
Accepted 25 January 2016
Available online 25 January 2016
Keywords:
Terbinaﬁne hydrochloride
Analytical methods
Pharmaceuticals
Biological materialsx.doi.org/10.1016/j.jpha.2016.01.003
79/& 2016 Xi'an Jiaotong University. Producti
reativecommons.org/licenses/by-nc-nd/4.0/).
r review under responsibility of Xi’an Jiaotong
esponding author.
ail address: kanakapurabasavaiah@gmail.coma b s t r a c t
Terbinaﬁne is a new powerful antifungal agent indicated for both oral and topical treatment of myco-
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(B. Kanakapura).1. Introduction
Terbinaﬁne hydrochloride (TFH) (Fig. 1) is an allylamine deriva-
tive. Chemically, it is [(2E)-6,6-dimethylhept-2-en-4-yn-1-yl](methyl)
(naphthalen-1-ylmethyl)amine hydrochloride. Its molecular weightis is an open access article under the CC BY-NC-ND license
Fig. 1. Terbinaﬁne hydrochloride.
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melts at 195–198 °C (changes in crystal structure begin at 150 °C).
TFH is freely soluble in methanol and methylene chloride; soluble in
ethanol; and slightly soluble in water [1]. Like all other allylamines, it
inhibits ergosterol synthesis by inhibiting squalence epoxidase an
enzyme that plays a role in fungal cell wall synthesis pathway [2]. In
laymans' terms, it inhibits the growth of fungal and bacterial cell
wall, leading to the death of the cell, as the contents of the cell are
unprotected. Therefore, it is applied to the skin in the occurrence of
dermatophytoses, pityriasis versicolor and cutaneous candidiasis [3],
superﬁcial fungal infections like seborrheic dermatitis, tineacapatis,
and onychomycosis especially for its short-duration therapy [4].
Generally, TFH is the main chemical form of terbinaﬁne for phar-
maceutical purposes. It comes as a tablet for oral administration, and
is usually taken once a day for 6 weeks for ﬁngernail fungus treat-
ment and once a day for 12 weeks for toenail fungus treatment. The
cream and powder formulations of the drug are used for superﬁcial
skin infections such as jock itch (tineacrusis), athlete's foot (tinea-
pedis) and ringworm. Terbinaﬁne is highly lipophilic in nature and
tends to accumulate in skin, nails and fatty tissues. Excessive terbi-
naﬁne may cause some side effects such as allergic reactions (difﬁ-
culty in breathing, throat closing, and swelling of hips, tongue, face
and liver), rash, and changes in vision and blood problems [5].
Because of its therapeutical importance, quantitative determi-
nation of terbinaﬁne in pharmaceuticals and human physiological
ﬂuids is of considerable signiﬁcance in both quality control of
preparations and chemical diagnosis. In the last approximately 25
years, several methods have been reported for the determination
of terbinaﬁne in pharmaceuticals and biological materials includ-
ing body ﬂuids. The current review surveys the methods
developed to determine terbinaﬁne in drug, drug products, body
ﬂuids and other biological materials.2. Methods for pharmaceuticals
2.1. Pharmacopoeial methods
TFH is an ofﬁcial drug in European Pharmacopoeia [6], British
Pharmacopoeia [7] and United States Pharmacopoeia [8]. Eur-
opean Pharmacopoeia and British Pharmacopoeia describe a ti-
trimetric procedure in which 250 mg of TFH is dissolved in 50 mL
of 96% ethanol, 5.0 mL of 0.01 mol/L HCl is added, and the un-
reacted HCl is titrated with 0.1 mol/L NaOH, and the end point is
determined potentiometrically. The volume of NaOH added be-
tween the two inﬂection points corresponds to the amount of TFH.
In the method described in United States Pharmacopoeia, TFH
assay was done by using high performance liquid chromatography
(HPLC), in which C18 (150 mm3.0 mm, 5 mm) column was used
as stationary phase and the mobile phase was composed of buffer
(0.2% triethylamine in water, pH was adjusted to 7.5 with dilute
acetic acid), acetonitrile and methanol with a gradient elution.
Column temperature was set at 40 °C and the ﬂow rate at 0.8 mL/
min. Column efﬂuent was monitored at 280 nm.2.2. Titrimetric method
Other than the ofﬁcial methods [6,7], a titrimetric method in
which TFH in anhydrous acetic acid mediumwas titrated with 0.05
mol/L acetous perchloric acid using crystal violet indicator has
been described [9]. The method was applied to bulk drug and
tablets with recoveries of 100.41% and 101.81%, respectively, and a
coefﬁcient of variation of 1.64.
2.3. UV-spectrophotometric methods
In the same article [9], an UV-spectrophotometric method was
described for the determination of TFH in raw materials, tablets
and creams. The calibration graph was linear over the concentra-
tion range of 0.8–2.8 mg/mL (r¼0.9997) with a recovery close to
100% from the formulations and a coefﬁcient of variation of about
10. Absorbance measurement of a methanolic solution of the drug
at 223 nm has facilitated its determination in a concentration
range of 1–3.5 mg/mL (r2¼0.999) with limit of detection (LOD) and
limit of quantiﬁcation (LOQ) values of 0.11 and 0.33 mg/mL, re-
spectively. The method was applied to Fintrix coated 250 mg ta-
blets with an accuracy of 0.08% (relative error, RE) [10]. In a similar
method [11], absorbance of drug solution in methanol was mea-
sured at 282 nm and the method was applied to Tebif 250 mg
tablets with an accuracy of 0.02% (RE). Beer's law was obeyed over
a concentration range of 8–24 mg/mL with an LOD of 0.35 mg/mL
and an LOQ of 0.81 mg/mL. Intra- and inter-day precisions were
o0.5% (relative standard deviation, RSD).
Two UV-spectrophotometric methods which are stability-in-
dicating [12] and based on the absorbance measurement of drug in
0.1 mol/L HCl at 222 nm (method A) and in 0.1 mol/L acetic acid at
282 nm (method B) were described for bulk drug and tablets.
Beer's law was obeyed over the concentration ranges of 0.2–
4.0 mg/mL and 2.0–50 mg/mL for method A and method B, re-
spectively, with corresponding molar absorptivities of 8.72104
and 7.97103 L/mol/cm. The methods were applied to the de-
termination of TFH in tablets with a good accuracy (REr1.26%)
and precision (RSDr0.32%) and without detectable interference
from tablet excipients. The drug was subjected to acidic, basic,
hydrolytic, oxidative, thermal and photo degradation and used to
assess the stability-indicating power of the methods. In both the
methods, the drug was found to undergo slight degradation under
base-induced stress conditions, substantial degradation under an
oxidative stress condition, and non-degradation under other stress
conditions. Another UV-spectrophotometric method employing
0.1 mol/L HCl as the medium and 223 nm as the wavelength of
maximum absorbance was also reported [13]. The calibration
graph was linear over a concentration range of 1–3.5 mg/mL
(r2¼0.995), and LOD and LOQ values were 0.086 and 0.260 mg/mL,
respectively. The method, when applied to coated tablets, was
found to be accurate (REo1%) and precise (RSD around 2%). Ab-
sorbance of an aqueous solution of the drug was measured at
283 nm serving as the basis of the method for TFH in bulk and
tablet forms. The method was valid over the concentration range
of 5–30 mg/mL with LOD and LOQ values of 0.42 and 1.30 mg/mL,
respectively. The method was applied to eye drops and the results
were found to be satisfactory with an RE of 0.81% and an RSD of
1.34%. The method was also demonstrated to be rugged [14].
Two UV-spectrophotometric methods developed for the
quantiﬁcation of TFH in the presence of its degradation products
[15] make use of the ﬁrst spectral derivation (1D) and the ﬁrst
derivative of the ratio spectra (1DD) of the drug and its photo-
degradates at different selected wavelengths. Good linearity was
observed in the range of 10–100 mg/mL with an LOD of
1.11 mg/mL and an LOQ of 3.36 mg/mL. The methods reported
show good accuracy and precision.
Table 1
Performance characteristics of UV-spectrophotometric methods.
S.No. Diluent λmax (nm) Linear range (mg/mL); molar extinction
coefﬁcient, Є (L/mol/cm)
LOD (mg/mL) LOQ (mg/mL) Application Reference
1 – – 0.8–2.8 – – Bulk drug, tablets, creams [9]
2 Methanol 223 1–3.5 0.11 0.33 Tablets [10]
3 Methanol 282 8–24 0.35 0.81 Tablets [11]
4 (a) 0.1 mol/L HCl 222 0.2–4.0; 8.72104 – – Bulk drug, tablets SIAM [12]
(b) 0.1 mol/L acetic acid 282 2.0–50; 7.97103 – – Bulk drug, tablets SIAM
5 0.1 mol/L HCl 223 1–3.5 0.086 0.26 Tablets [13]
6 Water 283 5–30 0.42 1.3 Bulk drug, tablets, eye drops [14]
7 – – 10–100 mg/mL 1.11 mg/mL 3.36 mg/mL In the presence of degradation
products
[15]
8 – 297; 298 5–30 – – Tablets, creams [16]
SIAM: Stability-indicating assay method.
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onide was achieved by employing two UV-spectrophotometric
methods [16]. The ﬁrst method is concerned with the determi-
nation of both drugs using ﬁrst derivative (D1) mode at 297 and
274 nm over the concentration ranges of 5–30 and 4–20 mg/mL,
respectively. The second method depends on ratio spectra 1st
derivative (RSD(1)) spectrometry at 298 and 248 nm over the
same concentration ranges. The methods were applied to the de-
termination of the drug in Limisil and Kenacort tablets and Limisil
cream with a recovery of 99.35%–100.9% and an RSD of o1%. The
details of UV-spectrophotometric analysis are summarized in
Table 1.
2.4. Visible spectrophotometric methods
Apart from UV-spectrophotometric methods, there are four
reports dealing with the application of visible spectrophotometry
for the assay of TFH in pharmaceuticals. TFH was reported to form
an ion-pair complex with methyl orange (1:1) in buffer medium of
pH 2.6, and the complex was extracted into chloroform and
measured at 422 nm. This served as a basis for the assay of drug in
tablets [17]. The calibration graph was linear over the range of 6–
12 mg/mL TFH (r¼0.9997) with a molar absorptivity of
1.89104 L/mol/cm. The log conditional stability constant (Kf) was
determined to be 5.2870.25/mol (n¼5). The method was proved
to be selective against tablet excipients and applied to the de-
termination of drug in Terbisil tablets with an RE of 0.22% and an
RSD of 1.22%. Effects of nature of buffer and pH, and reagent
concentration were reported and optimized. Three more extractive
spectrophotometric methods [18] based on the formation of co-
lored ion-pair complexes between TFH and molybdenum
(V) thiocyanate (method A), Orange G (method B) or alizarin red S
(method C) have also been described. The formed complexes were
extracted with organic solvent and absorbance was measured at
470, 500 and 425 nm for methods A, B and C, respectively. The
analytical parameters and their effects on the three systems were
investigated. The methods permitted the determination of TFH
over the concentration ranges of 5–75 mg/mL (method A), 10–
80 mg/mL (method B) and 5–55 mg/mL (method C).
Three acidic triphenylmethane dyes, i.e., bromothymol blue
(BTB), bromophenol blue (BPB) and bromocresol green (BCG),
were reported to form chloroform-soluble ion-pair complexes
with TFH in acidic medium. These reactions were used to develop
three sensitive and selective visible spectrophotometric methods
for the determination of the drug in formulations [19]. All the
three extracted complexes showed maximum absorbance at
410 nm. The effects of dye concentration, nature of buffer and pH
have been studied and optimized. Beer's law was obeyed over theconcentration range of 2–25 mg/mL in all methods with a molar
absorptivity value of about 2.0105 L/mol/cm. The LOD values
were 0.24, 0.28 and 0.54 mg/mL for BTB, BPB and BCG, respectively,
and the respective LOQ values were evaluated to be 0.71, 0.84, and
1.62 mg/mL. The methods, when applied to Terbicip 250 mg tablets,
yielded results close to 100% recovery with an RSD value of o1%.
The results compared excellently with those of the reference
method based on Student's t-test and variance ratio F-test. The
molar ratio between TFH and the dyes was also established and
found to be 1:1 in all cases. The formation constants (K) of the
ion-pair complexes were in the range of 1.13106–1.34106/mol.
Relying on different reaction schemes, drug in pure state and ta-
blets was assayed by three simple spectrophotometric methods
[20]. The ﬁrst two methods are indirect and are based on the se-
lective oxidation of the drug by chloramine T (CAT method) or
permanganate (KMnO4 method) in acidic medium followed by the
determination of residual oxidant by reacting with either gallo-
cyanine and measuring the absorbance at 540 nm (CAT method) or
reacting with fast green FCF and measuring the absorbance at
620 nm (KMnO4 method). The third method relies on the forma-
tion of colored charge-transfer complex with 2,3-dichloro-5,6-di-
cyano-1,4-benzoquinone, in which the absorbance of the radical
anion in acetonitrile was measured at 450 nm. Through charge-
transfer complexation reaction with iodine [21], the drug was
determined in the concentration range of 2102–1103 mol/L
by measuring the absorbance of the complex formed in CHCl3
medium at 512 nm. The details of these methods are summarized in
Table 2.
2.5. Spectroﬂuorimetric method
Based on the measurement of native ﬂuorescence of TFH in water
at 376 nm after excitation at 275 nm, a rapid and highly sensitive
spectroﬂuorimetric method has been reported for TFH in pharma-
ceuticals [22]. The ﬂuorescence-concentration plot was linear over
the concentration range of 0.02–0.05 mg/mL (r¼0.9998) with LOD
and LOQ values of 0.0031 and 0.0094 mg/mL, respectively. The
method was applied to the determination of TFH in commercial ta-
blets, cream, gel and spray formulations with an RE of o1% and
an RSD of o2%. This information is also shown in Table 2.
2.6. Electrochemical methods
The electrochemical oxidation of terbinaﬁne with boron-doped
diamond (BDD) and glassy carbon (GC) electrodes was examined and
applied to the determination of the drugs in pharmaceuticals [23].
The studies were performed by cyclic voltammetry (CV), differential
pulse voltammetry (DPV) and square wave voltammetry (SWV). The
Table 2
Performance characteristics of visible-spectrophotometric and spectroﬂuorometric methods.
S.
No.
Reagent Methods Methods Linear range
(mg/mL); molar extinction
coefﬁcient, Є (L/mol/cm)
LOD
(mg/mL)
LOQ
(mg/mL)
Application Reference
1 MO TFH-MO ion-pair extracted into CHCl3 and measured at
422 nm.
6–12; 1.89104 – – Tablets [17]
2 (a) Mo(V)-SCN TFH-Mo(V)-SCN; TFH-OG; and TFH-ARS ion-pair com-
plexes were extracted into organic solvents and absor-
bance measured at 470, 500 and 425 nm,
respectively
5–75 – – Bulk drug [18]
(b) OG 10–80 – – Bulk drug
(c) ARS 5–55 – – Bulk drug
3 (a) BTB Drug-dye ion pair complexes formed in acid medium
extracted into CHCl3 and measured at 410 nm
2–25; 2.0105 0.24 0.71 Tablets [19]
(b) BPB 2–25; 2.0105 0.28 0.84 Tablets
(c) BCG 2–25; 2.0105 0.54 1.62 Tablets
4 (a) CAT-GLN Unbleached dye color measured at 540 nm – – – Bulk drug, tablets [20]
(b) KMnO4-FG FCF Unbleached dye color measured at 620 nm. – – – Bulk drug, tablets
(c) DDQ Charge-transfer complex formed in acetonitrile measured
at 450 nm
– – – Bulk drug, tablets
5 Iodine Drug-I2 charge-transfer complex formed in chloroform
measured at 512 nm
2102–1103 mol/L – – – [21]
6 Spectroﬂuorimetry-
Water
Native ﬂuorescence in water was measured at 376 nm
after excitation at 275 nm
0.02–0.05 0.0031 0.0094 Tablets, cream, gel
and spray, spiked
human plasma
[22]
MO: Methyl orange; Mo(V)-SCN: Molybdenum (V) thiocyanate; OG: Orange G; ARS: Alizarin red S; BTB: Bromothymol blue; BPB: Bromophenol blue; BCG: Bromocresol
green; CAT: Chloramine T; GLN: Gallocyanine; KMnO4: potassium permanganate; FG FCF: fast green FCF; DDQ: 2,3-dichloro-5,6-dicyano-1,4-benzoquinone.
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rates were investigated and optimized. Using BDD electrode, a linear
relationship between diffusion current and concentration was ob-
tained in the concentration ranges of 5.44107–5.18106 mol/L
by SWV and 7.75107–8.55106 mol/L by DPV. For the GC
electrode, linear relationship was found in the concentration ranges
of 7.75107–8.55106 mol/L and 7.75107–1.05105 mol/L
by SWV and DPV, respectively. The developed methods were applied
to determine the drug in tablets and cream with a recovery in the
range of 99.49%–101.41% and a standard deviation of 0.31%–1.89%.
The effects of various reducing substances and metal ions on the
voltammetric signal were also studied. PVC membrane sensor as an
indicator electrode has been applied for the potentiometric assay of
TFH [24]. The sensing element of the PVC membrane was made from
the interaction of TFH and sodium tetraphenylborate, and the best
PVC membrane was composed of 30% PVC, 62% dibutylphosphate, 6%
ion-pair and 2% ionic liquid. The glass cell where terbinaﬁne-PVC
membrane was placed consisted of two Ag/AgCl double junction
reference electrodes which acted as internal and external reference
electrodes. The sensor demonstrated advanced performance with a
fast response time, a lower detection limit of 6.65106 mol/L and
potential responses across the range of 7106 to 1102 mol/L.
The sensor enabled the determination of TFH in tablets with sa-
tisfactory results (94.3%–105.4% of the labeled amounts). The se-
lectivity coefﬁcients of various interfering compounds were also
evaluated by the matched potential method. Using manganese and
zinc thiocyanate complexes, ( ) −Mn SCN 42 and ( ) −Zn SCN 42 as titrants
through ion association complex formation reactions with TFH, the
drug was determined in pharmaceuticals by conductometric titration
[25]. The method was reported to be highly precise with an RSD of
o1%. The solubility products of the resulting ion-associates were
also determined. Terbinaﬁne was found to be adsorbed on a hanging
drop mercury electrode at pH 6 giving a single wave at 1.47 V vs
Ag/AgCl reference electrode, due to oleﬁnic double bond reduction.
This led to the determination of the drug by voltammetry [26]. The
electrochemical process was found to be irreversible and funda-
mentally adsorption-controlled. A systematic study of the several
instrumental and accumulation variables affecting the adsorptive
stripping (Ads) response was carried out using square wavevoltammetry (SWV) and differential pulse voltammetry (DPV) as
redissolution techniques. The LOD values were 1.71010 mol/L
(Ads-SWV) and 6.3107 mol/L (Ads-DPV). For the determination
of the drug in Lamisil tablets and spiked human urine, a preparation
step at a solid phase C18 cartridge and an Ads-SWV procedure were
used and the results were precise with an RSD of o3%. Methods and
performance characteristics of the electrochemical methods are
compiled in Table 3.
2.7. Chromatographic methods
In an effort to optimize a liquid chromatographic method for
quantitative analysis of terbinaﬁne in formulations [27], the se-
paration was carried out on an RP-C18 (250mm4.6 mm, 5 mm)
vertical column using methanol–water (95:5, v/v) as mobile phase
at a ﬂow rate of 1.2 mL/min with UV-detection at 254 nm. The
detector response was linear over the concentration range of 20–
200 μg/mL (r¼0.9997) with LOD and LOQ values of 0.9 and
2.7 μg/mL, respectively. The method was applied to determine
terbinaﬁne in pharmaceutical hydroalcoholic solutions and tablets
with recoveries of 99.2%–99.8% for pharmaceutical solutions and
100.9%–102.1% for tablets. The method was also employed for a
dissolution test. The tablet dissolution test was so fast that 80% of
the drug was dissolved within 15 min. The method was also
shown to be accurate, precise, speciﬁc and robust.
Using a C18 column as stationary phase and a 0.2% aqueous
solution of sodium-1-heptanesulphonate (as an ion-pairing re-
agent) of pH 2 (adjusted with H3PO4)-acetonitrile (60:40, v/v) as
mobile phase, TFH in tablets was determined by ion-pair reversed-
phase-liquid chromatography [28]. The detection wavelength was
set at 220 nm and the method was applied over a concentration
range of 8.54–59.8 μg/mL, with LOD and LOQ values of 1.21 and
3.67 μg/mL, respectively. The method’s repeatability was 0.90%
(RSD) and reproducibility was 0.92% (RSD). When applied to
250 mg tablets, the method yielded results which were accurate to
99.83% of label claim with a standard deviation of 0.29. The
chromatogram of the tablet extract did not show additional peaks,
which proved the selectivity of the method against the tablet
excipients.
Table 3
Performance characteristics of electrochemical methods.
S.No. Methods Linear range (mol/L) LOD (mol/L) LOQ (mol/L) Application Reference
1 (a) DPV using (i)BDD electrode (i) 7.75107–8.55106 – – Tablets and cream [23]
(ii) GC electrode (ii)7.75107–1.05105
(b) SWV using (iii) BDD electrode (iii) 5.44107–5.18106 – –
(iv) GC electrode (iv) 7.75107–8.55106
2 Potentiometric assay; PVC membrane
sensor
7106–1102 6.65106 – Tablets [24]
3 Conductometric titration; ( ) −Mn SCN 42
and ( ) −Zn SCN 42
– – – Pharmaceuticals [25]
4 (a) Voltammetry; SWV – 1.71010 – Tablets and spiked human urine [26]
(b) Voltammetry; DPV – 6.3107 – Tablets and spiked human urine
5 DPV: GC electrode 8108–5105 2.5108 – Human serum, clinical and pharmacoki-
netic studies
[46]
DPV: Differential pulse voltammetry; SWV: Square wave voltammetry; BDD: Boron-doped diamond; GC: Glassy carbon.
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phase consisting of buffer-acetonitrile (65:35, v/v) pumped at a
ﬂow rate of 1.8 mL/min with UV-detection at 220 nm [29]. The
calibration graph was linear over the concentration range of 0.02–
2 mg/mL. The method showed excellent precision with intra- and
inter-day variation of o2% (RSD) and high accuracy with an RE of
0.9%. The method was applied to determine TFH in 250 mg tablets
of three brands and the average drug content was 99.52% of label
claim with a standard deviation of 0.95.
By carrying out chromatography on an ODS column using a
mixture of phosphate buffer and acetonitrile (60:40, v/v) as mobile
phase at a ﬂow rate of 1 mL/min with UV-detection at 283 nm,
TFH in tablets was assayed by a reversed-phase-high performance
liquid chromatography (RP-HPLC) method [30]. The retention time
of the drug was 7.1 min. The method produced linear response in
the concentration range of 0.5–50 mg/mL (r¼0.998). The method
exhibited excellent intra- and inter-day precisions with RSD values
of r1.04% and r1.44%, respectively. The method was applied to
quantify the drug content in Daskil and Fungoteck tablets each
containing 250 mg of TFH. The mean amounts (mg) of the drug
obtained were 252.670.44 (Daskil) and 249.370.31 (Fungotech)
indicating remarkable accuracy and precision of the method.
Chromatography was performed on an Inertsil C18 column to
assay TFH in semi-solid dosage forms by HPLC [31]. The mobile phase
consisted of methanol and acetonitrile (60:40, v/v) with 0.15% trie-
thylamine and 0.15% H3PO4 (pH 7.68) and eluents were monitored by
photodiode array (PDA) detector set at 224 nm. The method was
claimed to have been statistically validated for linear range, LOD,
LOQ, accuracy, precision, speciﬁcity and robustness. The linear range
was 5 to 50 mg/mL with LOD and LOQ values of 0.1 and 0.2 mg/mL,
respectively. To develop an RP-HPLC method for TFH in cream for-
mulation [32], chromatography was performed on a phenomenex C18
column (250 mm4.6 mm, 5 mm) using water–acetonitrile–metha-
nol (50:40:10, v/v/v) containing 0.1 mL of H3PO4 and triethylamine
respectively as mobile phase with UV-detection at 282 nm. TFH
present along with chlorhexidine and triamcinolone acetonide
acetate in compound ointment has been determined using Kramosil
C18 5 mm column [33]. A 0.3% sodium heptanesulphonate in metha-
nol of pH 3.2 (adjusted with glacial acetic acid)-distilled water (73:27,
v/v) was the mobile phase with UV-detection at 248 nm. The
method, besides sensitive and speciﬁc, was accurate for the de-
termination of three components with good resolution.
To accomplish simultaneous assay of TFH and bezaﬁbrate in
pharmaceutical dosage forms, separation and analysis were
achieved by gradient elution on a C18 column with water–
ammonium dihydrogenphosphate–methanol (15:25:60, v/v/v) as
mobile phase. The mobile phase ﬂow rate was 1 mL/min and theefﬂuents were detected at 225 nm. The calibration graph was
linear over the concentration range of 2–12 mg/mL (r¼0.999)and
LOD and LOQ values were 0.05 and 0.15 mg/mL, respectively. The
method was found to be accurate with an RE of 0.46% and precise
with an RSD of 0.75% [34].
Terbinaﬁne in the presence of its photo-degradation products
was determined by liquid chromatography [35] using an RP-μ-
Bondapak C18 column (250 mm4.6 mm, 10 μm) as stationary
phase and water-methanol (20:80, v/v) as mobile phase with UV-
detection at 284 nm. The method showed a signiﬁcant stability-
indicating ability with good linearity, precision and accuracy. As-
say of TFH in tablets and creams has been reported using a Shim-
pack CLC-ODS (250 mm4 mm, 5 μm) column with water-me-
thanol (5:95, v/v) as mobile phase in an isocratic mode at a ﬂow
rate of 1 mL/min and UV-detection at 254 nm. The calibration
graph was linear over the range of 10–20 mg/mL (r2¼0.9994). The
method yielded excellent results when applied to tablets and
creams, with an RE of 1.15%–3.3% and an RSD o1% [36]. The
method was also validated for intra- and inter-day precisions (RSD,
0.02%–1.23%).
There are two reports describing the stability-indicating assay
for the drug by HPLC. In a method applicable to bulk drugs
and tablets, the analysis was carried out on a NeoSphere
C18 (250 mm4.6 mm, 5 μm) column with a mobile phase
comprising of methanol and 0.5% triethanolamine at a ﬂow rate of
1.2 mL/min with a runtime of 8 min, and the eluents were mon-
itored at 250 nm. The method was valid over the concentration
range of 2–12 mg/mL with an LOD of 0.22 mg/mL and an LOQ of
0.66 mg/mL. The method was applied to tablets with satisfactory
results and tablet excipients did not interfere in the assay [10]. As a
part of stability-indicating assay, the drug was subjected to acid,
base, and neutral (water) hydrolysis, and oxidative, thermal and
photo degradation, and the drug was found to undergo slight
degradation under acidic and photolytic stress conditions and to
be unaffected under other stress conditions. In the second HPLC
method devoted for the stability-indicating assay [37], separation
and analysis were carried out on a ZORBAX Eclips XDB C18
(150 mm4.6 mm, 3.5 μm) column at 30 °C with UV-detection at
222 nm. The mobile phase comprised buffer prepared by mixing
1000 mL water with 2 mL triethylamine (pH adjusted to 3.4 with
triﬂuoroacetic acid): isopropyl alcohol: methanol (40:12:48, v/v/v)
at a ﬂow rate of 1 mL/min. An excellent linearity was obtained
over the range of 1–80 mg/mL with LOD and LOQ values of 0.3 and
1.0 mg/mL, respectively. The method, when applied to tablets,
yielded results which were in good agreement with those of a
reference method and were highly accurate and precise, and
without any detectable interference from tablet excipients. To
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drug was subjected to forced degradation in accordance with the
ICH guidelines, and the results indicated that the drug degraded
slightly under oxidative stress condition and remained stable un-
der other stress conditions.
Apart from being used for the quantitation of TFH in drug and
drug products, HPLC was also applied for the separation and de-
termination of the drug and its four impurities of similar structure
[38]. In an improved RP-HPLC method, the active component,
terbinaﬁne, its one impurity, 1-methylaminomethylnaphthalene,
and three degradation products, β-terbinaﬁne, z-terbinaﬁne and
4-methylterbinaﬁne occurring in pharmaceutical formulations
after long-term stability tests, were determined simultaneously
using propylparaben as an internal standard. The chromatographic
separation was performed on a NUCLEOSIL 100-5-CN column and
the mobile phase for the separation of all compounds consisted of
sodium citrate buffer of pH 4.5, tetrahydrofuran, and acetonitrile
(70:10:20, v/v/v) at a ﬂow rate of 0.8 mL/min, with UV-detection at
226 nm. The method was validated and system suitability para-
meters were investigated. LOD value for terbinaﬁne degradation
products or impurities was 0.023–0.098 mg/mL and LOQ value was
0.078–0.327 mg/mL. The method robustness and short-term stan-
dard solution stability were also veriﬁed. The method, which is
claimed, is applicable for routine determination of terbinaﬁne and
all its found impurities of similar structure with sufﬁcient se-
lectivity, precision and accuracy.
Spectrodensitometric assay of TFH along with triamcinolone
was achieved after separation by thin layer chromatography (TLC)
[16]. It is a rapid and precise method for the separation and
quantiﬁcation of both TFH and triamcinolone. The assay was done
by densitometric evaluation at 283 and 238 nm for TFH and
triamcinolone, respectively. The method was applicable over the
concentration ranges of 5–25 mg/spot (TFH) and 2.5–22.5 mg/spot
(triamcinolone). The method was applied to the assay of TFH in
laboratory prepared mixtures and pharmaceutical preparations
and the results were in excellent agreement with those of a re-
ference method. Terbinaﬁne and its degradation products were
assayed by a method [35] which depended on coupling the TLC-
fractionation on silica gel 60F254 utilizing chloroform–methanol-
25% aqueous ammonia (12:0.1:0.1, v/v/v) as mobile phase with
direct scanning at 284 nm.
In addition to TLC, high performance thin layer chromato-
graphy (HPTLC) also ﬁnds application for the assay of TFH in
pharmaceuticals. In a method that could be applied to routine
analysis [39], separation was achieved on aluminum plates pre-
coated with silica gel 60F254, with toluene–ethylacetate–formic
acid (4.5:5.5:0.1, v/v/v) as mobile phase, and densitometric ana-
lysis was performed at 284 nm. Compact band of the drug was
obtained at an Rf value of 0.3170.02. Linearity (r2¼0.9985), LOQ
(0.035 mg/band), recovery (97.6%–109.6%) and precision (RSDr2.19%)
were satisfactory. The method was reported to be applicable for
accelerated stability-testing of the drug in pharmaceutical drug-
delivery systems. Since the method was found to effectively se-
parate the drug from its degradation products, it could be used as a
stability-indicating one. In another method [40], pre-coated silica
gel 60F254 aluminum foil TLC plate was used as stationary phase
and the chromatogram was developed using n-hexane:acetone:
glacialaceticacid (8:2:0.1, v/v/v) as mobile phase. A compact band
at an Rf value of 0.42 was obtained for terbinaﬁne. Densitometric
analysis was performed in the absorbance mode at 223 nm using
Camag TLC scanner. Linear relationship of peak area and drug
concentration was excellent (r2¼0.9997) in the concentration
range of 0.2–1 mg/spot. The LOD and LOQ values were 0.0012 and
0.0036 mg/spot, respectively. The method was applied to bulk
drugs and tablets with satisfactory results. The drug was subjected
to acid, alkali, hydrolytic, oxidative, photochemical and thermaldegradation, and the drug was found to undergo degradation only
under photochemical stress condition by exposure to UV-light. An
HPTLC method has been described for the assay of TFH in tablets
[41] by employing aluminum back pre-coated silica gel 60F254 TLC
plates as stationary phase and acetonitrile:1,4-dioxane:hexane:
acetic acid (1:1:8:0.1, v/v/v/v) as mobile phase. After developing
the chromatogram in a Camag chamber, densitometric scanning
was performed with Camag TLC scanner-3 at 282 nm. The Rf value
was 0.45. The standard graph was linear over the range of 0.5–
5 mg/spot (r2¼0.9975). The LOD and LOQ values were 0.30 and
0.39 mg/spot, respectively. The method was found to be precise
with RSD values of 0.55%–0.97% (intra-day, n¼3) and 0.33%–0.84%
(inter-day, n¼3). On applying the method to 250 mg commercial
tablets, the method yielded results (249.87 mg) very close to the
label claim. Tables 4 and 5 present the gist of these methods.
2.8. Capillary electrophoresis methods
A capillary electrophoresis method developed for the separa-
tion and determination of terbinaﬁne in various pharmaceutically
relevant mixtures [42] involved separation by capillary zone
electrophoresis and UV-absorbance detection at 224 nm. The se-
paration and analysis were performed using a hydrodynamically
closed 160 mm capillary tube (300 μm i.d.). The inﬂuences of pH,
carrier cation and counter ion on migration parameters of the drug
were studied. The method was applicable over the concentration
range of 6–60 mmol/L with an LOD of 1.73 mmol/L. Under optimum
conditions described, the method was applied to the determina-
tion of terbinaﬁne in commercial tablets and sprays with an RE of
0.64% (tablets) and 0.53% (sprays). Another article described an
electrochemical method involving capillary electrophoresis (CE)
with contactless conductivity detection, and amperometry asso-
ciated with batch injection analysis, for the determination of TFH
in pharmaceutical products [43]. In the CE method, terbinaﬁne
was protonated and analyzed in the cationic form within 1 min. A
linear range from 1.46 to 36.4 μg/mL in acetate buffer solution and
an LOD of 0.11 μg/mL were achieved. In amperometric studies,
terbinaﬁne was oxidized at þ 85 V with high throughput
(225 injections/h) and good linear range (10–1000 mmol/L). There
was also a description of the assay for this antifungal agent using
simultaneous conductometric and potentiometric titrations in the
presence of 5% ethanol with NaOH as titrant. Electrochemical
methods were applied to the quantiﬁcation of TFH in different
samples, and the results agreed with the label claim and were
comparable to those found using pharmacopoeial titrimetric
method.
Two rapid and efﬁcient electrophoresis methods (phosphate
buffer method and formic acid method) have been developed for
the analysis of terbinaﬁne by capillary zone electrophoresis [44].
Resolutions higher than 1.5 were achieved with 0.025 mol/L
phosphate buffer (pH 2.30) and 0.2 mol/L formic acid (pH 2.15)
with an applied voltage of 20 kV and a temperature of 30 °C. Both
methods yielded calibration graphs which were linear over a
concentration range 0.5–15 μg/mL. The LOD and LOQ values were
0.40 and 1.30 μg/mL (phosphate buffer method) and 0.22 and
0.72 μg/mL (formic acid method). Better sensitivity and selectivity
were achieved in phosphate buffer whereas formic acid system
yielded shorter analysis time. The reproducibility obtained for
migration time (RSDr1.0%, n¼10) and peak areas (RSDr4.3%,
n¼10) were acceptable. These details are summarized in Table 6.
2.9. Microbiological assay
A microbiological assay, applying the cylinder-plate method for
the determination of TFH, has been optimized [45]. Using a strain
of Aspergillus ﬂavus ATCC 15546 as the test organism, TFH with
Table 4
Performance characteristics of HPLC, UPLC and GC methods.
S.No. Stationary phase; Mobile phase UV-detection
(nm)
Linear range
(μg/mL)
LOD (μg/mL) LOQ (μg/mL) Application Reference
1 C18 (150mm3.0 mm, 5 μm); Buffer (0.2% triethyl-
amine in water, pH 7.5 with acetic acid), acetoni-
trile, and methanol; 0.8 mL/min.
280 – – – Bulk drug [8] (USP
method)
2 RP-C18(250mm4.6 mm, 5 μm); methanol–water
(95:5, v/v); 1.2 mL/min.
254 20–200 0.9 2.7 Pharmaceutical
hydroalcoholic
solutions and
tablets, dissolution
test
[27]
3 C18; 0.2% sodium-1-heptanesulphonate: acetonitrile
(60:40, v/v)
220 8.54–59.8 1.21 3.67 Tablets [28]
4 RP-C18; buffer:acetonitrile (65:35, v/v); 1.8 mL/min 220 0.02–2 – – Tablets [29]
5 ODS column; phosphate buffer:acetonitrile
(60:40, v/v); 1 mL/min
283 0.5–50 – – Tablets [30]
6 Inertsil C18; methanol:acetonitrile (60:40, v/v) with
0.15% triethylamine and 0.15% H3PO4 (pH 7.68)
224 5–50 0.1 0.2 Semi-solid dosage
forms
[31]
7 Phenomenex C18 (250mm4.6 mm, 5 μm); water–
acetonitrile–methanol (50:40:10, v/v/v)
282 – – – Cream [32]
8 Kramosil C18; distilled water-0.3% sodium heptane-
sulphonate in methanol (pH 3.2 with glacial acetic
acid) (73:27, v/v)
248 – – – Ointment [33]
9 C18 column; water–ammonium dihydrogen-
phosphate–methanol (15:25:60, v/v/v); 1 mL/min.
225 2–12 0.05 0.15 Dosage forms [34]
10 RP-Bondapak C18 (250mm4.6 mm, 10 μm);
water–methanol (20:80, v/v)
284 – – – In the presence of
photo degradation
products (SIAM)
[35]
11 Shim-pack CLC-ODS (2504 mm, 5 μm); water:
methanol (5:95, v/v); 1 mL/min.
254 10–20 – – Tablets and creams [36]
12 NeoSphere C18 (250mm4.6 mm, 5 μm); 0.5%
triethanolamine and methanol; 1.2 mL/min
250 2–12 0.22 0.66 Stability-indicating
assay; bulk drug and
tablets
[10]
13 ZORBAX Eclips XDB C18 (150mm4.6 mm, 3.5 μm);
0.2% triethylamine buffer (pH 3.4 with tri-
ﬂuoroacetic acid):isopropyl alcohol:methanol
(40:12:48, v/v/v); 1 mL/min.
222 1–80 0.3 1.0 Stability-indicating
assay, tablets
[37]
14 NUCLEOSIL 100-5-CN; Sodium citrate buffer
(pH 4.5)-tetrahydrofuran–acetonitrile
(70:10:20, v/v/v); 0.8 mL/min
226 – – – Separation of
impurities
[38]
15 Buffer (0.012 mol/L triethylamineþ0.02 mol/
L H3PO4) and acetonitrile (50:50, v/v)
224 0.02–2 0.002 – Human plasma, nail,
sebum, and stratum
corneum; Pharma-
cokinetic solution
[49]
16 Phenyl column 224 0–2.5 (plasma) 0.02–0.5 – Human plasma and
urine
[50]
0–1 (urine)
17 MerckLichro CART (250mm4 mm, 5 μm);
0.05% aqueous triﬂuoroacetic acid, acetonitrile,
and methanol
224 0.1–15 0.31 0.95 Urine [51]
18 – UV and elec-
tro chemical
– 0.05
(plasma)
– Plasma, milk and
urine
[52]
0.15 (milk)
0.3 (urine)
19 C18 column; water and acetonitrile (60:40, v/v)
containing H3PO4 (0.02 mol/L) and triethylamine
(0.01 mol/L)
224 1–3 mg/g (skin) – 0.1 mg/g (skin) Rat tissues [53]
0.01–0.6 mg/g
(other tissues)
0.01 mg/g
(other tissue)
20 – – – – Nail samples [54]
21 (a) Pecosphere 3 C18 (83mm4.6 mm, 3 μm);
0.012 mol/L triethylamineþ0.02 mol/L H3PO4:
acetonitrile (48:52, v/v); 2.0 mL/min.
224 (HPLC) 0.0003–3 – 0.01 μg/g Cat hair [55]
(b) Capillary HP-5 column (30 m250 μm0.25 μm);
carrier gas was helium
FID Detector
(GC)
0.025–5 – 0.0006 mg/g –
22 ZORBAX SB-Aq C18 column; 50% H3PO4:acetonitrile
(40:60, v/v); 0.8 mL/min.
– – – – Human plasma [56]
23 Hypersil GOLD C18 (50mm2.1 mm, 1.7 μm);
0.1% formic acid and acetonitrile (UPLC)
– – 0.01–0.07 – Plasma and urine [57]
SIAM: Stability-indicating assay method.
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perspective validation of the method showed good linearity
(r¼0.9998), precision (RSDo1.0%) and accuracy when applied to
tablets and creams. The assay was found to be satisfactory for the
quantiﬁcation of in vitro antifungal activity of terbinaﬁne (Table 7).3. Methods for biological materials
Most of the methods developed for the determination of TFH in
biological materials are based on different modes of liquid chro-
matography, and a few methods relying on spectroﬂuorimetry,
Table 5
Performance characteristics of TLC and HPTLC methods.
S.No. Stationary phase; Mobile phase Detection (nm) Linear range
(mg/spot)
LOD (mg/
spot)
LOQ (mg/
spot)
Application Reference
1 Spectrodensitometry 283 5–25 – – Pharmaceutical preparations containing
TFH and triamcinolone
[16]
2 Silica gel 60F254; 25% aqueous ammonia–
chloroform–methanol (0.1:12:0.1, v/v/v)
284 – – – Bulk drug, degradation products [35]
3 Silica gel 60F254; Formic acid-toluene–
ethylacetate (0.1:4.5:5.5, v/v/v)
284 – – 0.035 Pharmaceuticals, accelerated stability
testing
[39]
4 Silica gel 60F254; n-hexane: acetone: gla-
cial acetic acid (8:2:0.1, v/v/v)
223 0.2–1 0.0012 0.0036 Bulk drug and tablets; SIAM [40]
5 Silica gel 60F254; acetonitrile: 1,4-dioxane:
hexane: acetic acid (1:1:8:0.1, v/v/v/v)
282 0.5–5 0.30 0.39 Tablets [41]
SIAM: Stability-indicating assay method.
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3.1. Spectroﬂuorimetric method
The spectroﬂuorimetric method described earlier for dosage
forms [22] was extended to the determination of the drug in
spiked human plasma and the results were satisfactory with a
mean recovery of (99.5771.04)% (Table 2).
3.2. Electrochemical methods
Voltammetric determination of TFH in human serum samples
using GC electrode modiﬁed by cysteic acid or carbon nanotubes
composite ﬁlm was conducted without pretreatment of biological
ﬂuid [46]. The determination of TFH at the modiﬁed electrode was
studied by DPV. The peak current obtained at þ1.556 V (vs SCE)
from DPV was linearly dependent on the drug concentration in the
range of 8108–5105 mol/L (r¼0.998) in a Britton–Robinson
buffer solution of pH 1.81 and an LOD value of 2.5108 mol/L.
The low-cost modiﬁed electrode showed good sensitivity, se-
lectivity and stability. It was supposed that the method could be
applied to clinical and pharmacokinetic studies (Table 3).
3.3. Microbiological assay
Using a strain of Aspergillus ﬂavus as the test organism, a
speciﬁc agar diffusion bioassay for antifungal agent in blood
serum, has been described [47]. The method was sensitive and
could be applied over the concentration range of 0.2–6.4 μg/mL. In
one of the earliest studies [48], a bioassay with trichophyton
mentagrophytes was described for SF86-327, an allylamine anti-
fungal agent (TFH). The drug concentration in serum was mea-
sured by bioassay in 117 serum samples from ﬁve patients re-
ceiving 500 mg/day. The peak, trough, and area under the con-
centration-time curve were determined after the ﬁrst dose and at
steady state condition. Drug accumulation occurred in prolonged
therapy. The method was applicable over the concentration rangeTable 6
Methodology and performance characteristics of capillary electrophoresis methods.
S.No. Buffer Detection (nm) Linear range (μg
1 – 224 6–60 μmol/L
2 Acetate buffer solution Conductivity and
amperometry
1.46–36.4
10–1000 μmol/L
3 (a) Phosphate buffer (pH 2.30) – 0.5–15
(b) Formic acid (pH 2.15) – 0.5–15
4 0.05 μmol/L 220 –
Phosphate buffer (pH 2.2)of 0.16–10 μg/mL and the RSD values were high at the lowest
concentrations. The method also used for organism with potential
causing skin infections. Despite these limitations, it was a simple
and useful method for determination of drug concentration in
serum. Summary of these assays is presented in Table 7.
3.4. Chromatographic methods
Terbinaﬁne and its desmethyl metabolite in human plasma
have been determined by RP-HPLC [49]. The analytes and the in-
ternal standard were separated by liquid-liquid extraction fol-
lowed by an aqueous back extraction before injecting the aqueous
layer to HPLC system. The mobile phase consisted of acetonitrile
and 0.012 mol/L triethylamineþ0.02 mol/L H3PO4 (50:50, v/v) and
the efﬂuents were monitored at 224 nm. The analytes were de-
termined in the concentration range of 0.02–2 mg/mL with an RSD
of 2.9%–9.8%. Because of the very high sensitivity (LOD,
0.002 mg/mL), it could be applied to pharmacokinetic studies.With
additional pretreatment steps, it was supposed that the method
could be used for assaying the drug in tissues such as nail, sebum,
and stratum corneum. An isocratic HPLC method using on-line
solid phase extraction has been described for the simultaneous
determination of terbinaﬁne and its ﬁve metabolites in human
plasma and urine [50]. The compounds were separated on a
phenyl column following on-line solid phase sample cleanup with
a column-switching device. The drug and its metabolites were
detected by monitoring the efﬂuents at 224 nm. The drug and its
metabolites were assessed in the range of 0–2.5 mg/mL in plasma
and 0–1 mg/mL in urine LOQ values based on a 20% bias ranged
from 0.02 to 0.5 mg/mL depending on the compound and matrix.
However, the extraction efﬁciencies from the body ﬂuids ranged
from 55%–100% due to the considerable differences in hydro-
phobicity of the compounds.
A new and reliable gradient RP-HPLC method with a diode
array detector (DAD) was developed and validated for the de-
termination of terbinaﬁne in urine [51]. The analysis was achieved
on a Merck LiChroCART analytical (250 mm4 mm, 5 mm) column/mL) LOD (μg/mL) LOQ (μg/mL) Application Reference
1.73 μmol/L – Tablets and sprays [42]
0.11 – Pharmaceutical products [43]
0.40 1.30 – [44]
0.22 0.72 –
0.08 μmol 0.28 μmol Body ﬂuids [62]
Table 7
Performance characteristics of microbiological assay methods.
S.No. Method; Strain Linear range
(μg/mL)
LOD (μg/mL) LOQ (μg/mL) Application Reference
1 Cylinder-plate method; Aspergillus ﬂavus (ATCC
15546)
0.125–0.5 – – Tablets and creams; in vitro antifungal
activity of TFH
[45]
2 Strain of Aspergillus ﬂavus – 0.2–6.4 – Blood serum [47]
3 Trichophyton mentagrophytes 0.16–10 – – Serum [48]
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ﬂuoroaceticacid, acetonitrile and methanol. The efﬂuent was
monitored by a DAD at 224 nm. The calibration graph was linear
over the concentration range of 0.1–15 μg/mL with LOD and LOQ
values of 0.31 and 0.95 μg/mL, respectively. The method applying
to spiked human urine sample was found to be accurate with a
percent bias of 0.06%–6% and the precision (RSD) ranged from 1.3%
to 5.41%.
Analytical procedures were developed for the determination of
terbinaﬁne (I) and its dimethyl derivative (II) in plasma, milk and
urine, and the metabolite carboxyterbinaﬁne (III) in plasma and
urine, as well as further metabolites, dimethyl carboxy terbinaﬁne
(IV) and naphtholic acid (V) in urine by HPLC [52]. The methods for
plasma analysis employed either electrochemical detection (for I
and II) or UV-detection (for III) following a protein precipitation
with methanol or solvent extraction with hexane as appropriate.
For quantitative analysis of substances I-IV, native urine samples
were deconjugated, mixed with the internal standard and injected
by an autosampler into a microprocessor-controlled HPLC system.
The substances were monitored by UV-absorption. The metabolite
V was determined in the urine after deconjugation, sample pre-
paration with commercially available cartridge, and silylation by
automated GC with fused silica capillary column and ﬂame ioni-
zation detection (FID). The LOD for I and II was 0.05 mg/mL in
plasma and 0.15 mg/mL in milk, and 0.1 mg/mL for III in plasma. The
detection limit in urine was 0.3 mg/mL for I–IV analyzed by HPLC.
HPLC was also used for the simultaneous determination of
terbinaﬁne and its metabolite N-dimethyl terbinaﬁne in rat tissues
[53]. The method involved the homogenization of tissues (except
for skin) followed by a liquid–liquid extraction. Skin samples were
dissolved in NaOH prior to extraction. The drug and its metabolites
were assayed using a RP-C18 column with a mobile phase com-
posed of water and acetonitrile (60:40, v/v) containing H3PO4
(0.02 mol/L) and triethylamine (0.01 mol/L). UV-detection was at
224 nm, and clotrimazole was used as the internal standard. The
standard curve for the assay was linear over the range of 0.1–3 mg/
g in skin and 0.01–0.6 mg/g in all other tissues. The LOQ was 0.1 mg/
g for skin and 0.01 mg/g for all other tissues. The precision (RSD)
lay between 0.2% and 16%. In a related method, terbinaﬁne in nail
samples of patients treated orally with terbinaﬁne for onycho-
mycoses has been determined [54]. After extraction, the samples
were measured by HPLC, and the results indicate rapid penetration
of the drug into normal nail plate. Two methods using HPLC and
GC have been compared and critically evaluated for the determi-
nation of TFH levels in cat hair after appropriate sample pre-
treatment, hydrolysis of hair samples followed by liquid–liquid
extraction [55]. The HPLC was performed on a Pecosphere 3 C18
(83 mm4.6 mm, 3 mm) column maintained at 45 °C. The mobile
phase consisted of acetonitrile: 0.012 mol/L triethylamineþ0.02 mol/L
H3PO4 (52:48, v/v) at a ﬂow rate of 2 mL/min with an isocratic
elution mode, and the detector was set at 224 nm. The GC system
used a capillary HP-5 coated with 5% phenyl methyl siloxane
(30 m250 mm0.25 mm) on a temperature gradient mode using
an FID detector. The carrier gas was helium at a ﬂow rate of
11.8 mL/min. The HPLC method for the determination of TFH in cat
hair had a linearity of 0.0003–3 mg/mL with an LOQ of 0.01 μg/g.With a linear range of 0.025–5 mg/mL and an LOQ of 0.0006 mg/g,
the GC method was less sensitive compared to the HPLC method.
And the latter was more accurate with a recovery of 93.8% against
a recovery of 70% achieved by GC.
With ZORBAX SB-Aq C18 column, the optimized HPLC system
was applied to the determination of terbinaﬁne in human plasma
[56] with a mobile phase consisting of 50% H3PO4–acetonitrile
(40:60, v/v) at the ﬂow rate of 0.8 mL/min using paraben
as the internal standard (IS). The retention time was 17.43 and
7.27 min for the drug and IS, respectively. The developed method
was transferred to UPLC with similar column packing, Water
Aquity BEH C18 (50 mm2.1 mm, 1.7 mm) column, and 50%
H3PO4-acetonitrile (50:50, v/v) as mobile phase at a ﬂow rate of
0.3 mL/min. The retention time of terbinaﬁne and IS were 2.98 and
0.92 min, respectively. By this transfer, the analysis time was re-
duced by a factor of 6 compared to HPLC with a similar peak ca-
pacity. Simultaneous determination of furosemide and its active
metabolite suluamine, spironolactone and its active metabolite
canrenone, terbinaﬁne and its metabolite N-demethylcarboxy
terbinaﬁne, and vancomycin in human plasma and urine have
been determined by RP-UPLC with UV-detection [57]. Good se-
paration and analysis of the analytes were achieved on a Hypersil
GOLD C18 (50 mm2.1 mm, 1.7 mm) column in 3.3 min with 0.1%
formic acidand acetonitrile as the mobile phase. The LOD values
varied from 0.1 to 0.07 μg/mL with vancomycin as an exception
(0.11 μg/mL). The analysis was preceded by protein precipitation
and solid phase extraction of the analytes from plasma and urine
samples. Owing to short analysis time and small quantities of
samples required, the methods could be advantageously applied to
routine clinical analysis. Summary of these methods is presented
in Tables 4 and 5.
3.5. Liquid chromatography–mass spectrometric methods
A fully automated high throughput liquid chromatography/
tandem mass spectrometric (LC–MS/MS) method was developed
for terbinaﬁne quantiﬁcation in human plasma [58]. The drug and
the internal standard (N-methyl-1-napthalenemethylamine) after
extraction from human plasma by liquid–liquid extraction using a
mixture of methyl tertiary butyl ether-hexane (70:30, v/v) as the
organic solvent were analyzed on a reversed-phase LC-MS/MS
with positive ion electrospray ionization and multiple reaction
monitoring. The calibration curve was linear for 0.005–2 mg/mL
concentration range, and the method had a very short sample
preparation time and chromatographic runtime of 2.2 min. Hence,
the method was applied to the rapid and reliable determination of
the drug in plasma in a bioequivalence study after oral adminis-
tration of 250 mg tablet of terbinaﬁne. Using the same technique
(LC–MS/MS), the determination of terbinaﬁne in human and
minipig plasma has been developed and validated [59]. The
method used a positive ion mode to monitor terbinaﬁne and used
a stable isotope labeled terbinaﬁne as the internal standard. Sub-
sequent to acetonitrile protein precipitation, the unﬁltered su-
pernatant portion was injected on the LC column (retention time
of nearly 4.3 min). The lower limit of quantiﬁcation (LLOQ) was
0.0000679 mg/mL in human and minipig plasma using a plasma
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ciﬁc, was demonstrated to exhibit ruggedness.
In an approach to applying the quantiﬁcation of terbinaﬁne in
human plasma to bioequivalence study, the drug was assayed by
HPLC coupled to electrospray tandem mass spectrometry [60]. The
method used nuftiﬁne as the internal standard and had a chro-
matographic runtime of 5 min. The standard plot was linear in the
range of 0.001–2 mg/mL with an LOD of 0.001 mg/mL. The intra-day
precision and accuracy were r4.1% (RSD) and r7.8% (RE), re-
spectively. The method was used in a bioequivalence study of two
250 mg tablets of terbinaﬁne. An LC–MS/MS instrument equipped
with an electrospray ionization interface and operated in the po-
sitive ion mode of detection was used to determine terbinaﬁne in
human hair [61]. The procedure involved hydrolysis of 10 mg of
human hair with 0.5 mL of 5 mol/L NaOH for 90 min followed by
extraction with 1.5 mL of n-hexane. The separated organic layer
was re-extracted with 0.2 mL of 12.5% formic acid and 2-propanaol
(85:15, v/v). The aqueous layer was separated and 0.01 mL of the
aqueous extract was injected onto an RP-microbore (50 mm0.1 mm
i.d) column for analysis. The method showed excellent speciﬁcity
and ruggedness with an LLOQ of 0.01 mg/g using 10 mg of human
hair. Gist of these methods is presented in Table 8.
3.6. Capillary electrophoresis method
A rapid and simple capillary zone electrophoresis method for
the determination of terbinaﬁne and eight of its main metabolites
after incubation with rat hepatic S9 fraction was developed [62].
All the nine components were base-line resolved in less than
4 min using a 0.05 mol/L phosphate buffer (pH 2.2) without ad-
ditives, after a solid phase cleanup procedure for these in vitro
samples. A voltage of 15 kV was applied in separation and elec-
tropherograms were recorded at 220 nm. An LOD of 0.08 μg/mL
and an LOQ of 0.28 μg/mL were obtained.4. Challenges and conclusions
The review of the analytical methods reported for terbinaﬁne
showed that spectrophotometric, spectroﬂuorimetric, electro-
chemical, chromatographic, microbiological and capillary electro-
phoretic techniques have been applied to the determination of
TFH in pharmaceuticals and biological materials. However, the
HPLC with UV-detection system has been widely used for phar-
maceuticals, and HPLC with mass and tandem mass spectrometric
detector system has been largely employed for biological
materials.
The reviewed UV-spectrophotometric methods lacked wide linear
dynamic ranges and sensitivity, which could be tackled by enhancing
the aqueous solubility of the drug using strategies such as covalent
solubilization and micellar solubilization. In spite of the drug's ability
to form colored products with a number of chromogenic agents, onlyTable 8
Performance characteristics of liquid chromatography–mass spectrophotometric(LC–MS
S.No. Method Detection Linear range
(mg/mL)
1 LC–MS/MS with positive ion elec-
trospray ionization
Multiple reaction
monitoring
0.005–2
2 LC–MS/MS Positive ion mode
Monitoring
–
3 LC–MS/MS Positive ion mode
detection
0.001–2
4 LC–MS/MS Positive ion mode
detection
–a limited number of visible spectrophotometric methods based on a
few reactions have been reported. There is some scope for develop-
ing methods based on ion-association reactions using many acidic
anionic dyes, charge-transfer complexation reactions using sub-
stituted p-benzoquinone, polynitro phenols, nitro derivatives, etc.,
and oxidative coupling reactions involving MBTH and oxidants like
cerium (IV), iron (III), iodate, dichromate, etc. The reviewed extractive
spectrophotometric methods based on ion-association reactions
were plagued by several disadvantages. In recent years, there has
been a surge in the use of spectrophotometry without liquid-liquid
extraction step as a sensitive tool in pharmaceutical analysis [63–79].
This new approach can be used in place of extractive spectro-
photometry for terbinaﬁne. The sensitivity and selectivity of the re-
ported acid dye technique [17–19] can be further improved by dis-
solving the formed ion-pair in either alcoholic H2SO4 or alcoholic
KOH and measuring the dye color at appropriate wavelengths. The
high sensitivity of the modiﬁed approach allows the determination of
the drug in body ﬂuids after appropriate sample treatment [80].
RP-HPLC with UV-detection is the most widely used chroma-
tographic method for the determination of terbinaﬁne in phar-
maceuticals due to its high separation potential, selectivity and
sensitivity. However, HPLC with other detector systems such as
ﬂuorescence, electrochemistry, capillary electrophoresis, MS or
MS/MS is yet to be reported. With the advent of the International
Conference on Harmonization (ICH) guidelines, the requirement of
establishment of stability-indicating assay method (SIAM) has
become more clearly mandated. The guidelines explicitely require
conduct of forced decomposition studies under a variety of stress
conditions like pH, light, oxidation, dry heat, etc., and separation of
drug from degradation products, and the method is also expected to
allow analysis of individual degradation products [81,82]. None of
HPLC methods reviewed has addressed this concern though the only
stability-indicating HPLC method [38] is concerned with the separa-
tion and determination of three degradants formed after long-term
storage. However, separation and determination of the degradants
were not reported in the other two works [10,37]. A systematic and
comprehensive study is required to be done in this direction.
The reviewed UV-spectrophotometric [12] and HPTLC [39,40]
methods which are stability-indicating are concerned with bulk
drugs and the study needs to be extended to dosage forms. Organic
impurities can arise during the manufacturing process and storage
of the drug substances. The criteria for their acceptance up to cer-
tain limits are based on the pharmaceutical studies or known safety
data [83]. HPLC is the most convenient technique for the tasks of
separation, detection and quantitation of such impurities. Though
one impurity generated by long-term storage was assayed [38],
attempt has not been made to separate and determine the process-
related impurities by HPLC. Further, HPLC, despite being a versatile,
sensitive and selective technique, has failed to ﬁnd a mention in
pharmacokinetic or bioequivalence studies of the drug. Attention
has to be paid to developing HPLC methods for this study.
Most of the chromatographic methods reported for the) methods.
LOD (mg/mL) LLOQ Application Reference
– – Human plasma, bioequivalence
study
[58]
– 0.0000679 µg/mL Human and minipig plasma [59]
0.001 – Human plasma to bioequiva-
lence study
[60]
– 0.01 µg/g Human hair [61]
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plasma, serum, and urine relied on the use of HPLC with UV-de-
tection and LC with mass or tandem mass spectrometric detection
has been rarely used, and two such works by Dotsikas et al. [58] and
de Oliveira [60] are focused on bioequivalence study. Body ﬂuid is
highly complex and extraction of the drug and its active or inactive
metabolites has mainly been achieved with liquid–liquid extraction
using different solvent systems. Liquid–liquid extractions are useful
but have certain limitations. The extracting solvents are limited to
those that are water immiscible, emulsions tend to form when
solvents are shaken, and relatively large volumes of solvents are
used that generate a substantial waste disposal problem. The op-
erations are often manually performed and may require a back
extraction. However, many of these difﬁculties are avoided by the
use of solid phase extraction (SPE), which has become awidely used
technique for sample cleanup and concentration prior to chroma-
tographic analysis [84]. However, none of the chromatographic
methods reviewed uses SPE for the extraction of the drug or its
metabolites from biological materials. Due to the advantages of SPE,
it is likely that the methods, chromatography in particular, would be
developed in future using SPE.
HPLC with UV or MS detection is the most widely used tech-
nique for the analysis of drugs in pharmaceutical and biological
samples. The disadvantages of the technique are relatively long
runtime and consumption of large volumes of expensive organic
solvents creating the problem of waste disposal. In the last decade,
there have been attempts to transform pharmaceutical analysis
methods from HPLC to a relatively new technique, called UPLC,
thereby creating new possibilities in LC, especially concerning the
decrease in time and solvent consumption [85]. UPLC system al-
lows shortening analysis time up to 5–7 times while solvent
consumption is decreased by 6–9 times compared with conven-
tional HPLC. Besides, the sensitivity and the resolution were also
improved. In spite of these advantages, UPLC has never been ap-
plied for the assay of terbinaﬁne in pharmaceuticals, although one
HPLC method developed for human plasma [56] was transferred to
UPLC with reduction in the analysis time by a factor 6 and large
savings in terms of solvent consumption. Application of this new
approach in LC is worth considering in future research on analy-
tical method development for terbinaﬁne.
Electrochemical methods have been proven to be highly useful
for the assay of drugs, because of their sensitivity and selectivity.
The methods also allow a good understanding of electrode
mechanisms. Redox properties of drugs provide useful information
about their metabolic fate or their in vitro redox properties or
pharmaceutical activity [86,87]. Many voltammetric techniques
are highly sensitive which can determine electroactive species at
103–1011 mol/L concentration levels [88]. Though the terbina-
ﬁne molecule is electroactive, only four references are found in the
literature dealing with the determination of the drug in pharma-
ceuticals and only one method [46] has been extended to human
serum. Many more voltammetric techniques can be developed in
future targeting oleﬁnic double and triple bonds in the drug mo-
lecule. Electrochemical detection systems including amperometric
and conductometric detection can be incorporated into HPLC to
make it more versatile in the assay of the drug in pharmaceuticals
and biological materials.
In the last couple of decades, dynamic development of CE
methods for the analysis of drugs has been noticed [89,90], but the
method presents limited applications in the assay of terbinaﬁne
since only three references are found in the literature [42–44]; and
only one method by Grego et al. [62] was applied to body ﬂuids.
This might be due to its low sensitivity, which can be overcome by
coupling the techniques with MS or MS/MS.
Finally, a wide range of techniques are available for the assay of
terbinaﬁne in pharmaceuticals and biological materials. Analysis ofthe review of the methods reveals that HPLC with UV detection is
extensively used for the determination of the drug in pharma-
ceuticals and biological materials. Considering the speed, sensi-
tivity and cost effectiveness, direct UV spectrophotometry can be
used if the matrix effect is absent or derivative mode can be
considered as an alternative to circumvent the matrix effect.
Wherever possible, HPLC with UV detection can be regarded as a
better method since it is sensitive and selective, and the low cost
compared to most advanced detection systems. For the determi-
nation of the drug in biological samples, HPLC–MS/MS is ideally
suited since it combines the separation ability of HPLC with sen-
sitivity and selectivity of MS, which allows the unambiguous de-
tection of terbinaﬁne and its metabolites. It would be a greener
option if SPE precedes the analysis. This review presents an
overview of the current state of analytical methods for the de-
termination of terbinaﬁne.Acknowledgments
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